ONYX BIOTEC LIMITED Fair Value
ONYX · Healthcare · Current price ₹37.6
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹30 | 9% ROE fading to 12% over ~3 yrs, on ₹31 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | — | No analyst coverage |
Is ONYX BIOTEC LIMITED undervalued?
DocStoX estimates the fair value of ONYX BIOTEC LIMITED at ₹30 per share, versus the current market price of ₹38. That puts the stock about -20.2% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 1 independent method: Residual income (₹30). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹26 (bear) to ₹30 (base) to ₹35 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ONYX BIOTEC LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.